
Supplementary Figure S2



Supplementary Figure S2. Dual CDK4/6-MEK inhibition synergistically suppresses the growth of some, but not all, MPNST PDXs in immune deficient mice. The change in tumor volumes is shown for all xenograft tumors grown in immunodeficient mice. (A) S462 cell xenografts at the sciatic nerve of NSG mice were treated daily once tumors reached 250 mm^{3 with} vehicle, 12.5 mg/kg palbociclib (Palbo), 0.5 mg/kg mirdametinib (Mirda), or 12.5 mg/kg palbociclib plus 0.5 mg/kg mirdametinib combination (Combo). Panels B-F, PDXs from Johns Hopkins (JH) and Washington University at St. Louis (WU) were grown in the flank of female NRG mice. They were treated 5 days on/2 days off once tumors reached ~150 mm³ with vehicle, 75 mg/kg ribociclib (Ribo), 0.075 mg/kg trametinib (Tram) except for 0.15 mg/kg in JH-2-079c, or the combination (Combo) for the indicated treatment periods. Error bars, SEM. *P* values were determined by simple linear regression to determine statistical differences between slopes (*, P < 0.05; ***, P < 0.001).